Epithalon
A synthetic Khavinson tetrapeptide researched as a telomerase activator and pineal-gland bioregulator for anti-aging and melatonin/circadian normalization.
Epithalon (Ala-Glu-Asp-Gly; the AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a more stable analog of the natural pineal peptide epithalamin. It is the most-studied member of the Khavinson short-peptide bioregulator family, proposed to activate telomerase, elongate telomeres in aging somatic cells, normalize nocturnal melatonin secretion, and exert broad geroprotective effects. Its evidence base is substantial in patient-years but originates almost entirely from a single research group, with limited independent Western replication of the telomerase and lifespan claims.
Class
Synthetic tetrapeptide (pineal bioregulator)
Half-life
~30-60 minutes in plasma; downstream melatonin/circadian effects persist longer
Routes
Subcutaneous, Intravenous, Intranasal
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Telomerase activation & telomere elongation
Epithalon is proposed to enter the cell nucleus and activate the catalytic subunit of telomerase (hTERT), restoring telomerase activity in somatic cells where it is normally silenced. In vitro and rodent studies from the Khavinson group report telomere elongation, though independent replication is limited.
Melatonin & circadian normalization
As an epithalamin analog, Epithalon is studied for restoring age-related decline in nocturnal melatonin secretion and normalizing cortisol/melatonin diurnal rhythms. Cohort data in aged monkeys and elderly humans reported restored nighttime melatonin rhythms.
Sleep quality
The most consistent community-reported effect is improved sleep depth and quality, biologically plausible given the peptide's pineal-melatonin lineage, though not confirmed by Western clinical trials.
Antioxidant & anti-aging effects
Preclinical data associate Epithalon with upregulated antioxidant defenses (superoxide dismutase, catalase) and reduced oxidative damage markers (MDA, 8-OHdG) in aged tissues, consistent with its geroprotective positioning in the Khavinson framework.
Rodent lifespan extension & reduced tumor incidence
In studies from the originating lab, Epithalon modestly extended median and maximum lifespan (approximately +24% in SHR mice) and reduced spontaneous tumor incidence, chromosome aberrations, and carcinogenesis — data that argues against, rather than for, a cancer-promoting effect.
Neuroendocrine-immune regulation
The Khavinson framework proposes restoration of age-suppressed thymic and neuroendocrine-immune function; long-term cohort data reported reduced all-cause mortality when Epithalon was combined with Thymalin, though these studies were non-blinded.
Mechanism
How it works
Epithalon is a synthetic Ala-Glu-Asp-Gly (AEDG) tetrapeptide designed as a simplified, more stable analog of epithalamin, a natural pineal-gland peptide extract studied by Vladimir Khavinson's group since the 1970s. Its primary proposed mechanism is telomerase activation: the peptide is thought to enter cell nuclei and activate the catalytic subunit of telomerase (hTERT), restoring telomerase activity in somatic cells where it is normally repressed. This theoretically counteracts the age-related telomere shortening tied to cellular senescence and the Hayflick limit.
Beyond telomerase, the Khavinson bioregulator framework proposes broader epigenetic effects through direct DNA-promoter binding. A 2014 Khavinson study reported measurable changes in telomerase activity together with reduced methylation of specific gene promoters in cultured human cells, offering mechanistic support for chromatin-level gene-expression modulation. Epithalon also appears to regulate expression of p53 and other cell-cycle control genes and to upregulate antioxidant enzymes such as superoxide dismutase and catalase.
As an epithalamin analog, Epithalon acts on the pineal gland to normalize nocturnal melatonin secretion and restore physiological circadian rhythm regulation, which declines with age. Through this pineal-melatonin axis and modulation of the hypothalamic-pituitary and neuroendocrine-immune systems, the peptide is proposed to restore multiple physiological parameters that deteriorate during aging. Its plasma half-life is only minutes, but downstream effects on melatonin signaling and gene expression are proposed to persist well beyond clearance.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as a lyophilized powder; reconstitute with bacteriostatic water and store refrigerated after mixing. Mass-spectrometry identity confirmation (expected MW ~390.4 Da) is advised because Epithalon shares amino-acid composition with related Khavinson tetrapeptides such as Cardiogen and Cartalax.
Beginner
- Dose
- 5-10 mg per day
- Frequency
- Once daily (AM)
- Timing
- Morning
- Duration
- 10-day cycles every 6 months
- Route
- Subcutaneous
First-time anti-aging research protocol; bioregulator peptides are pulse-dosed in courses, not taken continuously.
Intermediate
- Dose
- 10-20 mg per day
- Frequency
- Once daily
- Timing
- Consistent daily timing
- Duration
- 10-20 day cycles every 4-6 months
- Route
- Subcutaneous or intranasal
Intranasal delivery is explored for direct CNS access via the olfactory pathway.
Advanced
- Dose
- 20-30 mg per day
- Frequency
- Split AM/PM doses
- Timing
- Morning and evening
- Duration
- 20-30 day cycles every 3-6 months
- Route
- Subcutaneous
Higher end of community protocols; sources note higher doses did not produce better outcomes and pulse-dosing (not continuous use) is the norm.
- No human clinical trial has established a standardized dosing regimen for Epithalon; community protocols derive from the Khavinson bioregulator framework and rodent research rather than validated human dose-ranging trials.
- Bioregulator peptides are administered in short pulse courses (typically 10-30 days) repeated every 3-6 months, not taken continuously.
- Russian gerontology literature used course-based administration, historically described as 10-20 injection courses in longevity research.
- Community reports note that results often take weeks to appear, higher doses did not improve outcomes, and effects can diminish on repeat cycles.
Evidence
Research & clinical studies (3)
Epithalamin and Epitalon peptides induce telomerase activity and telomere elongation in human somatic cells
Epitalon induced telomerase activity and telomere elongation in cultured human somatic cells and produced positive retinal effects in 90% of retinitis pigmentosa patients studied, representing early mechanistic evidence for its proposed anti-aging activity.
PMID 12195242Effect of epithalamin and epitalon on the melatonin-producing function of the pineal gland in elderly people and monkeys with pineal gland aging
Epithalamin and epitalon restored nighttime melatonin secretion rhythms in aged monkeys and elderly humans with age-related pineal decline, suggesting a regulatory role in neuroendocrine aging.
PMID 17969590Effect of Epitalon on the lifespan of rats
Epitalon administration was associated with extended lifespan and geroprotective effects in rats, part of the Khavinson-group rodent lifespan dataset (approximately +24% median lifespan reported in SHR mice).
Combinations
Stacking & blends
GHK-Cu + Epithalon: Anti-Aging
Longevity and tissue rejuvenation at both cellular-replication and tissue-maintenance levels
GHK-Cu resets gene expression toward a younger phenotype by activating antioxidant and anti-inflammatory gene networks, while Epithalon is proposed to slow cellular aging via telomerase activation and circadian/neuroendocrine regulation — complementary mechanisms addressing aging from two angles.
Thymalin + Epithalon: Immune-Longevity Protocol
Combined immune modulation and anti-aging
Both are short Khavinson bioregulators. Thymalin supports thymic peptide function and immune regulation in aging populations; Epithalon supports pineal activity, melatonin normalization, and telomere dynamics. Long-term cohort data reported reduced all-cause mortality with this pairing (non-blinded).
MK-677 + Epithalon: Sleep Architecture & Anti-Aging
Improved sleep architecture alongside longevity-related outcomes
MK-677 (ibutamoren), an orally active ghrelin mimetic, is researched for improving REM and slow-wave sleep and enhancing GH pulses; combined with Epithalon's pineal bioregulation and telomere dynamics, the stack targets both sleep quality and longevity.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy or lactation
- Active malignancy (theoretical telomerase/cancer concern)
- Known peptide allergy
- Acute autoimmune flare
Acute tolerability is generally mild, with injection-site reactions the most common report. The main safety gap is what has not been tested: no formal toxicology, genotoxicity, or carcinogenicity studies exist, and telomerase activation sits close to cancer biology in theory. Notably, the available rodent tumor data runs the opposite way (less carcinogenesis and fewer chromosome aberrations), though all such data comes from the originating lab and was not designed as oncology surveillance.
FAQ
Epithalon — common questions
What is Epithalon?
Epithalon (also spelled Epitalon) is a synthetic Ala-Glu-Asp-Gly tetrapeptide developed by Vladimir Khavinson in Russia in the 1980s as a stable analog of epithalamin, a pineal-gland peptide extract. It is the most-studied of the Khavinson short-peptide bioregulators, researched primarily for telomerase activation, telomere elongation, and anti-aging effects.
How does Epithalon work?
It is proposed to enter cell nuclei and activate the catalytic subunit of telomerase (hTERT), restoring telomerase activity and counteracting age-related telomere shortening. It is also proposed to exert epigenetic effects via DNA-promoter binding and to normalize nocturnal melatonin secretion and circadian rhythms through its pineal lineage.
What does the evidence actually show?
Preclinical studies report telomere elongation in cultured human cells and lifespan extension of roughly 24% in mice. Khavinson-group human cohorts with 10-15 year follow-up reported reduced all-cause mortality when Epithalon was combined with Thymalin, but these studies were non-blinded and originate predominantly from a single research group with limited independent Western replication.
How is Epithalon typically administered?
Community protocols use short pulse courses — commonly 5-30 mg per day subcutaneously (or intranasally) for 10-30 day cycles repeated every 3-6 months, not continuous use. No FDA-approved dosing regimen exists; these patterns derive from the Khavinson framework and rodent research.
Does Epithalon increase cancer risk?
Telomerase activation is theoretically a cancer-related mechanism, but Khavinson-group cohort data has not surfaced increased cancer incidence over 10-15 year follow-up, and rodent studies actually reported reduced tumor burden. However, those studies were not designed as oncology surveillance, so the theoretical concern remains unaddressed at Western clinical standards.
Is Epithalon FDA approved?
No. Epithalon has no FDA approval or approved indication anywhere in the world. It is sold as a research chemical. It was removed from the FDA's Category 2 bulk substances list on April 22, 2026 and scheduled for PCAC review in July 2026 — a procedural step that does not authorize compounding.
What are the reported side effects?
Reported effects are usually mild: vivid dreams, first-week sleep timing shifts, injection-site reactions, occasional headache, fatigue, or mood changes. The larger open question is long-term safety, which has not been established to Western standards.
How can I verify an Epithalon vendor?
Look for an independent third-party HPLC certificate of analysis from a lab the vendor does not own, ideally with mass-spectrometry identity confirmation (expected MW ~390.4 Da). Mass spec matters because Epithalon shares amino-acid composition with related Khavinson tetrapeptides like Cardiogen and Cartalax.
